What's new in blistering disorders?
From the characterization of new animal models for the study of disease pathogenesis, to the demonstration of new therapeutic modalities, many developments have revolutionized the field of autoimmune bullous diseases in the past several years. This review highlights many of the significant advances that have taken place in the diagnosis, pathogenesis, and treatment options for pemphigus, pemphigoid, epidermolysis bullosa acquisita, and immunoglobulin (Ig) A-mediated bullous disorders.
Chaudhari
Paru
P
Stanford University School of Medicine and VA Palo Alto Medical Center, 269 Campus Drive, Room 2145, Stanford, CA 94061, USA.
Marinkovich
M Peter
MP
D000818:Animals; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D001768:Blister / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D012872:Skin Diseases, Vesiculobullous / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy